Vaxxas
PrivateLast Round
Series D
Aug 25, 2025
Est. Valuation
$805M
Total Funding Raised
$168.59M
Company Overview
Vaxxas is a biotechnology company that develops a needle-free, patch-based vaccine delivery technology designed to improve vaccine performance and stability.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaxxas Comparables
Compare Vaxxas with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Micron Biomedical | 88% | |
| PharmaJet | 82% | |
| Verndari, Inc. | 82% |
Vaxxas Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 25, 2025 | ||||
| Debt | Aug 25, 2025 | ||||
| VC Round | Dec 5, 2022 | ||||
| Grant | Oct 1, 2022 | ||||
| Grant | May 28, 2020 | ||||
Series B | Apr 1, 2017 |
Key People
Founding team and executive leadership
Vaxxas Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UniQuest Pty Ltd | VC Round |
| The University of Queensland | Series B |
| OneVentures | Series D, Series A, VC Round, Series B |
| CEPI | Grant |
| Queensland Government | Grant |
| HealthCare Ventures | Series A, Series B |
| SPRIM Global Investments | Debt, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
David Peacock appointed as new CEO to lead commercialization.
- Nov 10, 2025
Brent MacGregor, veteran vaccine executive, joins the Board of Directors.
Recent news
Latest coverage and updates
- is_developingSep 24, 2026
Vaxxas is developing High-Density Microarray Platform.
Vaxxas Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vaxxas's valuation, stock price, and market status.
Is Vaxxas a public or private company?
Vaxxas is a private company.
What is the current stock price of Vaxxas?
Vaxxas is a private company with no public stock price. No recent secondary market data is available.
How much is Vaxxas worth (valuation)?
Vaxxas's valuation is estimated at $805.0M based on funding round data.
Can I buy Vaxxas stock?
Vaxxas shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vaxxas's last funding round?
Vaxxas's most recent funding round was Debt on August 25, 2025.
Who are the main investors in Vaxxas?
Key investors in Vaxxas include UniQuest Pty Ltd, OneVentures, SPRIM Global Investments, SPRIM Global Investments.
Will Vaxxas IPO soon?
No public IPO plans have been announced for Vaxxas.
How can I track Vaxxas secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vaxxas's secondary market activity and sign up for updates.